S. 2210, 110th Congress, Medical Innovation Prize Act of 2007

110th CONGRESS, 1st Session

S. 2210

To provide incentives for investment in research and development for new medicines, to enhance access to new medicines, and for other purposes.

IN THE SENATE OF THE UNITED STATES

October 19, 2007

Mr. SANDERS introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions


A BILL

Continue Reading

White House says ACTA text a State Secret. EU parliament says time for more transparency

On January 31, 2009, KEI submitted a Freedom of Information Act (FOIA) request to USTR for copies of seven documents containing much of the negotiating text of the proposed Anti-Counterfeiting Trade Agreement (ACTA). Today the White House office the United States Trade Representative denied the request, claiming the documents are “information that is properly classified in the interest of national security pursuant to Executive Order 12958.”

Continue Reading

Uncategorized

Impact of the HIF on generic industry in developing countries

This is an exchange from the ip-health list, that will be updated as the conversation continues, about the impact of the HIF on the generic drug industry developing countries.

—– Original Message —–
From: “James Love”
To: “Ip-health”

Cc: “Thomas Pogge” “Aidan Hollis”
Sent: Wednesday, November 19, 2008 2:15 PM
Subject: impact of the HIF on generic industry in developing countries

Continue Reading

Uncategorized

CDC FOIA shows US, WHO opposed request to discuss UNSG’s High-Level Panel on Access to Medicines Report at EB

Email records and memoranda released by the Centers for Disease Control (CDC) in response to a Knowledge Ecology International Freedom of Information Act (FOIA) request show that representatives of the World Health Organization (WHO) and the United States government opposed including India’s proposed agenda item on the United Nations Secretary-General’s High-Level Panel on Access to Medicines for discussion at the 140th WHO Executive Board meeting.

The full set of documents, which was released to KEI without redaction, are available here:

Continue Reading

2016: NIH FOIA office withholds all records related to exclusive license on HER2+ breast cancer treatment technology

Other KEI comments on NIH licenses are found here: /nih-licenses

In response to a February request under the Freedom of Information Act (FOIA) for documents related to the grant of an exclusive patent license on a HER2+ breast cancer treatment technology, the National Institutes of Health (NIH) withheld in full all responsive records.

Continue Reading

Uncategorized

USTR provides the names of the TPP Chapters (as of September 10, 2015)

On June 4, 2015, KEI asked USTR to provide the names of the TPP Chapters. The contents of the chapters are all officially secret, but we thought the names of the chapters should be public, and made a request for the chapter names under the Freedom of Information Act (FIOA). Today, more than 3 months later, USTR has responded to that FOIA. According to USTR, as of September 10, 2015, the names of the TPP Chapters are as follows:

  1. Intial Provisions and General Definitions
  2. Trade in Goods
  3. Textiles and Apparel
  4. Rules of Orgin
  5. Continue Reading

Uncategorized

Department of State FOIA Requests

  • On September 2009, KEI filed the following request under the Freedom of Information Act.
  • Request Date: 9/30/2009
    Request Reference Number: C6218

    The time period of my request is from 1/1/2009 to the present.

    Description of request:

    Continue Reading